

NOTICE OF NEW HAMPSHIRE MEDICAID PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE PUBLIC HEARING

April 16, 2009

The New Hampshire Pharmacy and Therapeutics Advisory Committee (PTAC) invites you to attend a public hearing at 2:00 p.m., on April 16, 2009 at the Howard Recreation Center, 99 Pleasant Street, State Office Park South, Concord, NH. A PTAC meeting will immediately follow this public hearing.

The purpose of the public hearing on April 16, 2009, is to solicit information and provide an opportunity for the public to present its views regarding the NH Medicaid preferred drug list and pharmacy prior authorization criteria.

The public hearing will begin at 2:00 p.m. and end no later than 3:00 p.m. The PTAC meeting will begin at or before 3:00 p.m., upon completion of public comments. The public is invited to present oral comments regarding the preferred drug list and prior authorization criteria for the April 16, 2009 public hearing. Members of the public shall notify the Department of Health and Human Services (DHHS) at least 48 hours in advance of the public hearing of their intent to comment at the public hearing. Comments will be limited to no longer than five (5) minutes per person and will be limited to the items on the agenda as they relate to the preferred drug list and prior authorization criteria.

Written material may also be submitted by the public for PTAC consideration if received by DHHS at least 48 hours in advance of the meeting and may not exceed five (5) pages in length.

PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING

April 16, 2009

Meeting Agenda

- I. Introductions and Welcome to Committee Members
- II. Old Business
 - a. Minutes – 11/6/08 review
- III. New Business
 1. Update on Pharmacy Lock-In Program
 2. Review of Current Preferred Drug List Therapeutic Classes with No Proposed Changes
 - Antibiotics – Herpetic Antivirals
 - Endocrinology – Growth Hormone
 - Gastrointestinal- Antiemetics
 - Respiratory – Inhaled Corticosteroids
 - Respiratory – Inhaled Corticosteroids Adrenergic and Combinations
 - Respiratory – Leukotriene Modifiers
 - Respiratory – Long Acting Beta Adrenergics and Combinations (Inhalers/Nebs)
 - Respiratory – Low Sedating Antihistamines and Combinations
 - Respiratory – Nasal Corticosteroids
 - Respiratory – Short Acting Beta Adrenergics and Combinations (Inhalers/Nebs)
 - Genitourinary/Renal – Urinary Antispasmodics
 - Genitourinary/Renal – Electrolyte Depleters
 - Ophthalmic/Antibiotic- Quinolones
 - Ophthalmic/Antihistamines- Antihistamines
 - Ophthalmic – Nonsteroidal Antiinflammatory
 - Central Nervous System – Interferons used to treat Multiple Sclerosis
 - Central Nervous System- Triptans and Combinations

3. Review of Proposed Preferred Drug List Therapeutic Classes
 - Respiratory – Nasal Antihistamines
4. Review of Current Clinical Prior Authorization Criteria with No Proposed Changes
 - Spiriva®
 - Xenical® for Hypercholesterolemia
5. Review of Current Clinical Prior Authorization Criteria with Proposed Changes
 - Amitiza®
 - Endocrinology – Growth Hormone
 - Synagis®
 - Weight Loss Medications
 - Xolair®
6. Review of Proposed Clinical Prior Authorization Criteria
 - Suboxone®

IV. Adjourn

Further information regarding the agenda items may be obtained after March 26, 2009, by contacting Robin Calley, at 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: rlcalley@dhhs.state.nh.us.

Notice of intent to testify at the April 16, 2009 public hearing, and/or submittal of written comments, should be directed to Robin Calley, Office of Medicaid Business and Policy, 129 Pleasant Street, Annex 1, Concord, NH, 03301, 1-800-852-3345, ext. 8166 (in state only), (603) 271-8166, or e-mail at: rlcalley@dhhs.state.nh.us.